Barclays analyst Carter Gould lowered the firm’s price target on Barinthus Biotherapeutics to $3 from $7 and keeps an Overweight rating on the shares. The analyst sees clarity on the company’s strategy after the workforce reduction and pipeline prioritization and notes its cash runway has been extended to Q2 of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
- Barinthus Biotherapeutics Breakthrough in Hepatitis B Treatment
- Barinthus presents EOT data from Phase 2a trial of imdusiran, VTP-300
- Barinthus Bio’s VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
- Arbutus announces preliminary EOT data from Phase 2a trial of imdusiran, VTP-300